Q. Salako

发表

A comparative study of copper‐67 radiolabeling and kinetic stabilities of antibody‐macrocycle chelate conjugates

G. Denardo, S. Denardo, D. Kukis, 1994, Cancer.

Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

G. Denardo, S. Denardo, S. Shen, 1998, Anticancer research.

Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.

S. Denardo, L. Miers, D. Kukis, 1995, Cancer research.

Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.

G. Denardo, S. Denardo, S. Shen, 1997, Anticancer research.

Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3)

G. Denardo, S. Denardo, S. Shen, 1994, Cancer.

Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.

G. Denardo, S. Denardo, C. Meares, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.

G. Denardo, S. Denardo, S. Shen, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Dosimetrie Evaluation of Copper-64 in Copper-67-2IT-BAT-Lym-l for Radioimmunotherapy

S. Denardo, S. Shen, A. Yuan, 2006 .

Analysis of long-lived radionuclidic impurities in short-lived radiopharmaceutical waste using gamma spectrometry.

S. Denardo, Q. Salako, 1997, Health physics.

Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.

S. Denardo, R. O’Donnell, Q. Salako, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioassay of yttrium-90 radiation using the radionuclide dose calibrator.

S. Denardo, Q. Salako, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Chelates for Radioimmunodiagnosis and Therapy'

S. Denardo, L. Miers, D. Kukis, 2006 .

Pharmacokinetics of Chimeric Ui Conjugated to Indium-ill-and Yttrium.90-DOTA-Peptide in Tumor-Bearing Mice

G. Denardo, S. Denardo, Min Li, 2006 .

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

J. McGahan, K. Lamborn, G. Denardo, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.

G. Denardo, S. Denardo, S. Shen, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.

R. Ceriani, G. Denardo, S. Denardo, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study.

G. Denardo, S. Denardo, S. Glenn, 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioiodination and preliminary in vivo investigation of the alkaloid cryptolepine.

S. Ablordeppey, Q. Salako, J. Thornback, 1985, The International journal of applied radiation and isotopes.

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

RADIOIMMUNOTHERAPY IN BREAST CANCER: CURRENT RESULTS IN PHASE I PROTOCOLS

R. Ceriani, G. Denardo, S. Denardo, 1992 .

Technetium-99m labelling of solubilized ligands—II

Q. Salako, A. Theobald, 1990 .

99mTc-labelling studies of solubilized ligands—Part I

Q. Salako, A. Theobald, 1989 .

Structure-distribution relationship studies of 99mTc-2,3-dioxime complexes.

Q. Salako, A. Theobald, 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.